Acupuncture needles take on belly fat in menopause study
NCT ID NCT07437001
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding electroacupuncture to a standard diet and medication plan can reduce central obesity and fatty liver in postmenopausal women. Sixty women aged 50-60 with obesity will receive the same diet and orlistat for 12 weeks, but half will also get electroacupuncture three times a week. Researchers will measure changes in BMI, waist and hip size, and liver enzymes to see if the acupuncture makes a difference.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- electroacupuncture
- What this could lead to
- If it works, this could point toward a non-drug way to reduce belly fat and liver fat in postmenopausal women.
- What could go wrong
- This is a small, early-stage trial with only 60 women. The results may not apply to everyone, and the added benefit of acupuncture over diet and medication alone is uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 60 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Their ages will be ranged between 50 and 60 years old. 2. Their body mass index will be ranged from 30-40 kg/m2. 3. SGOT more 40 U/L. 4. SGPT more 40 U/L. 5. Waist/Hip Ratio more 1 cm. 6. Triglyceride more 150 mg/dl. 7. Cholesterol more 200 mg/dl. 8. LDL more 100 mg/dl. 9. HDL less 40 mg/dl. Exclusion Criteria: 1. Cancer. 2. Concomitant cardiovascular disorders. 3. Respiratory, renal and liver dysfunction.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Fatty liver are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Aga Central Hospital
Aga, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple scan and blood test could catch silent liver scarring before It's too late
- A simple body scan may spot fatty liver disease without needles
- HIV and fatty liver: a hidden link under the microscope
- Can magnetic pulses calm an overactive bladder?
- Which cervical prep eases hysteroscopy for postmenopausal women?
- Liver's Post-Meal secrets could unlock new fatty liver treatments